JP7219721B2 - 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール - Google Patents

抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール Download PDF

Info

Publication number
JP7219721B2
JP7219721B2 JP2019556938A JP2019556938A JP7219721B2 JP 7219721 B2 JP7219721 B2 JP 7219721B2 JP 2019556938 A JP2019556938 A JP 2019556938A JP 2019556938 A JP2019556938 A JP 2019556938A JP 7219721 B2 JP7219721 B2 JP 7219721B2
Authority
JP
Japan
Prior art keywords
dose
antibody
patient
patients
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019556938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517648A (ja
JP2020517648A5 (enExample
Inventor
デーヴィッド・エイチ・マーゴリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2020517648A publication Critical patent/JP2020517648A/ja
Publication of JP2020517648A5 publication Critical patent/JP2020517648A5/ja
Priority to JP2023009976A priority Critical patent/JP2023052642A/ja
Application granted granted Critical
Publication of JP7219721B2 publication Critical patent/JP7219721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019556938A 2017-04-21 2018-04-20 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール Active JP7219721B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023009976A JP2023052642A (ja) 2017-04-21 2023-01-26 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762488630P 2017-04-21 2017-04-21
US62/488,630 2017-04-21
US201762575119P 2017-10-20 2017-10-20
US62/575,119 2017-10-20
US201862647301P 2018-03-23 2018-03-23
US62/647,301 2018-03-23
PCT/US2018/028616 WO2018195457A2 (en) 2017-04-21 2018-04-20 Treatment of multiple sclerosis with anti-cd52 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023009976A Division JP2023052642A (ja) 2017-04-21 2023-01-26 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール

Publications (3)

Publication Number Publication Date
JP2020517648A JP2020517648A (ja) 2020-06-18
JP2020517648A5 JP2020517648A5 (enExample) 2021-05-27
JP7219721B2 true JP7219721B2 (ja) 2023-02-08

Family

ID=62117065

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556938A Active JP7219721B2 (ja) 2017-04-21 2018-04-20 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
JP2023009976A Abandoned JP2023052642A (ja) 2017-04-21 2023-01-26 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023009976A Abandoned JP2023052642A (ja) 2017-04-21 2023-01-26 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール

Country Status (6)

Country Link
US (2) US20200299399A1 (enExample)
EP (1) EP3612564A2 (enExample)
JP (2) JP7219721B2 (enExample)
CN (1) CN110546167A (enExample)
TW (1) TW201841653A (enExample)
WO (1) WO2018195457A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526558A (ja) 2009-05-13 2012-11-01 ジェンザイム・コーポレーション 抗ヒトｃｄ５２免疫グロブリン
JP2016518333A (ja) 2013-03-15 2016-06-23 ジェンザイム・コーポレーション 抗ｃｄ５２抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2917882T3 (es) * 2006-09-13 2022-07-12 Alcafleu Man Gmbh & Co Kg Tratamiento de esclerosis múltiple (MS) con Campath-1H
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
EP3027187A4 (en) * 2013-08-01 2017-03-29 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
CN108025083B (zh) * 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526558A (ja) 2009-05-13 2012-11-01 ジェンザイム・コーポレーション 抗ヒトｃｄ５２免疫グロブリン
JP2016518333A (ja) 2013-03-15 2016-06-23 ジェンザイム・コーポレーション 抗ｃｄ５２抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COCHRANE DATABASE OF SYSTEMATIC REVIEWS，2016年，vol. 4，DOI: 10.1002/14651858.CD011203.pub2

Also Published As

Publication number Publication date
JP2020517648A (ja) 2020-06-18
TW201841653A (zh) 2018-12-01
US20230167189A1 (en) 2023-06-01
EP3612564A2 (en) 2020-02-26
US20200299399A1 (en) 2020-09-24
CN110546167A (zh) 2019-12-06
WO2018195457A2 (en) 2018-10-25
WO2018195457A3 (en) 2018-11-29
JP2023052642A (ja) 2023-04-11

Similar Documents

Publication Publication Date Title
KR102671283B1 (ko) 항tim-3 항체로 암을 치료하는 방법
JP5905534B2 (ja) 多発性硬化症を治療する方法
KR20060026860A (ko) 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
JP2022105160A (ja) 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ－ｃｓｆ
TW201521757A (zh) 先後通過利妥昔單抗（ｒｉｔｕｘｉｍａｂ）誘導治療及格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）治療
JP2013100313A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
JP2016527324A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
EP2367849A1 (en) Method for the treatment of neurodegenerative diseases
JP2017008106A (ja) ループス治療のための方法および組成物
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
KR20180073680A (ko) 포도막염 및 황반 부종의 치료를 위한 il6r 항체를 포함하는 조성물 및 이를 이용하는 방법
US20080317710A1 (en) Methods For Treating Autoimmune or Demyelinating Diseases
CN121152807A (zh) 使用抗cd40l抗体治疗多发性硬化症
CN112312971A (zh) 结合cd123和cd3的双特异性抗体的给药
KR20220166827A (ko) 혈청 IgG를 유지하면서 MS를 치료하기 위한 오파투무맙
Bhat et al. Intravenous daclizumab for recalcitrant ocular inflammatory disease
JP2023052642A (ja) 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
JP2021152002A (ja) 医薬組成物
CN1972714B (zh) 治疗自身免疫疾病和炎性疾病的方法
KR20210090211A (ko) 거대 세포 동맥염에 대한 치료
Soelberg Sorensen Intravenous polyclonal human immunoglobulins in multiple sclerosis
TW202222829A (zh) 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
JP3973360B2 (ja) 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
CA3153634A1 (en) Methods of treatment using omalizumab
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230127

R150 Certificate of patent or registration of utility model

Ref document number: 7219721

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150